Nektar Therapeutics (NKTR) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $60.76 (-0.56%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 13, 2026 | Jay Olson | Oppenheimer | $140.00 | +130.4% |
| Jan 26, 2026 | Yasmeen Rahimi | Piper Sandler | $105.00 | +72.8% |
| Dec 16, 2025 | Jay Olson | Oppenheimer | $115.00 | +89.3% |
| Nov 24, 2025 | Roger Song | Jefferies | $121.00 | +99.2% |
| Sep 18, 2025 | Roger Song | Jefferies | $99.00 | +62.9% |
| Apr 18, 2022 | Mara Goldstein | Mizuho Securities | $6.00 | -90.1% |
| Mar 1, 2022 | Jessica Fye | J.P. Morgan | $17.00 | -72.0% |
| Nov 8, 2021 | Aydin Huseynov | Ladenburg Thalmann & Co. | $20.00 | -67.1% |
| May 18, 2021 | Chris Shibutani | Goldman Sachs | $24.00 | -60.5% |
Top Analysts Covering NKTR
NKTR vs Sector & Market
| Metric | NKTR | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.18 | 2.24 | 2.40 |
| Analyst Count | 11 | 8 | 19 |
| Target Upside | +151.3% | +11474.9% | +17.1% |
| P/E Ratio | -10.37 | 3.92 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $40M | $42M | $43M | 9 |
| 2027-12-31 | $9M | $36M | $43M | 9 |
| 2028-03-31 | $8M | $11M | $12M | 2 |
| 2028-06-30 | $8M | $11M | $12M | 5 |
| 2028-09-30 | $8M | $11M | $12M | 4 |
| 2028-12-31 | $8M | $11M | $12M | 4 |
| 2029-03-31 | $8M | $11M | $13M | 5 |
| 2029-06-30 | $8M | $11M | $13M | 3 |
| 2029-09-30 | $8M | $11M | $13M | 3 |
| 2029-12-31 | $8M | $11M | $13M | 3 |
| 2030-12-31 | $99M | $189M | $217M | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-11.73 | $-9.59 | $-8.04 | 7 |
| 2027-12-31 | $-15.06 | $-12.13 | $-10.90 | 7 |
| 2028-03-31 | $-3.63 | $-3.04 | $-2.06 | 3 |
| 2028-06-30 | $-3.65 | $-3.05 | $-2.07 | 2 |
| 2028-09-30 | $-3.41 | $-2.85 | $-1.93 | 2 |
| 2028-12-31 | $-3.30 | $-2.76 | $-1.87 | 3 |
| 2029-03-31 | $-3.39 | $-2.84 | $-1.92 | 2 |
| 2029-06-30 | $-3.46 | $-2.89 | $-1.96 | 1 |
| 2029-09-30 | $-3.28 | $-2.74 | $-1.86 | 1 |
| 2029-12-31 | $-3.29 | $-2.76 | $-1.87 | 2 |
| 2030-12-31 | $-12.37 | $-10.38 | $-3.93 | 3 |
Frequently Asked Questions
What is the analyst consensus for NKTR?
The consensus among 11 analysts covering Nektar Therapeutics (NKTR) is Buy with an average price target of $132.83.
What is the highest price target for NKTR?
The highest price target for NKTR is $140.00, set by Jay Olson at Oppenheimer on 2026-03-13.
What is the lowest price target for NKTR?
The lowest price target for NKTR is $6.00, set by Mara Goldstein at Mizuho Securities on 2022-04-18.
How many analysts cover NKTR?
11 analysts have issued ratings for Nektar Therapeutics in the past 12 months.
Is NKTR a buy or sell right now?
Based on 11 analyst ratings, NKTR has a consensus rating of Buy (2.18/5) with a +151.3% upside to the consensus target of $132.83.
What are the earnings estimates for NKTR?
Analysts estimate NKTR will report EPS of $-9.59 for the period ending 2026-12-31, with revenue estimated at $42M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.